Parry Graham reported conversion involving 85,504 shares of Electra Therapeutics, Inc. on Sep 21, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
Chief Scientific Officer
Chief Scientific Officer
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
85,504Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
85,504Direct
Trade date
Sep 21, 2026Conversion
Filed
Sep 21, 2026, 6:17 PM ET0-day reporting delay
Accession
0002153366-26-000006Code C · Transaction 227054
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 21, 2026Conversion85,504——Trade 227055
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

ETRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ETRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Sep 28, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: 7,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026. F2: Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.